Niemann Pick Disease Type C Market Growth in Future Scope 2023-2030


 

Niemann-Pick Type C (NPC) is a rare inherited disease. This type of genetic mutation causes cholesterol and other fats to build up in the liver, spleen, or lungs. It has an impact on the brain as well. The onset of symptoms for NPC may begin at different ages. It has been grouped as: infantile (after birth to less than 6 years), juvenile (6 to 15 years), and adults (15 years to greater). In infants, NPC leads to disorders such as alpha-1-antitrypsin deficiency, tyrosinemia, Gaucher disease, idiopathic neonatal cholestasis, and various congenital infections.

Increasing government initiatives for rare diseases is expected to foster global niemann-pick disease type C treatment market growth over the forecast Period. For instance, in November 2021, the Italian senate unanimously approved the consolidated act on rare diseases. The aim of the act is to make the treatment of rare diseases uniform throughout the Italian territory and to promote progress in research. Moreover, the act also provides for the establishment of solidarity fund for people with rare diseases, with an initial budget of US$ 1.01 million per year starting from 2022.

Rising numbers of collaborations and agreements by market players are expected to drive growth of the global Niemann-pick disease drug type C treatment market over the forecast period. For instance, in May 2022, Kempharm, Inc., a specialty pharmaceutical company, announced an agreement with ORPHAZYME A/S, a global biopharmaceutical company, to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein (HSP) amplifier being developed as a treatment for Niemann-Pick disease type C (NPC)

Increasing research and development activities by market players are expected to drive growth of market over the forecast period. For instance, in June 2021, Cyclo Therapeutics, Inc., a clinical-stage biotechnology company, announced the commencement of its pivotal Phase 3 study (TransportNPC) for the evaluation of Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for treating Niemann-Pick Disease Type C1 (NPC1). The TransportNPC study is a randomized, double-blind, placebo-controlled, parallel group, multicenter study designed to evaluate the safety, tolerability, and efficacy of 2,000 mg/kg of Trappsol Cyclo administered intravenously and standard of care (SOC) compared to placebo administered intravenously and SOC in patients with NPC1.

Comments

Post a Comment

Popular posts from this blog

Mantle Cell Lymphoma Treatment Market will generate new growth opportunities 2023-2030

Image
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) that arises from abnormal B lymphocytes (a type of white blood cell) known as mantle cells. It is considered an aggressive subtype of NHL, and its treatment typically involves a combination of different approaches, including chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. Here is a detailed overview of the treatment options for mantle cell lymphoma : Chemotherapy: Chemotherapy drugs are commonly used as the initial treatment for MCL. The specific chemotherapy regimens may vary, but commonly used combinations include R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine), or Bendamustine combined with rituximab (BR). Chemotherapy is typically administered in cycles over several months. Immunotherapy: ...
Read more

Phosphodiesterase Enzyme (PDE) Inhibitors Market 2023 Report Contains Key Vendor Analysis, Vendor Landscape and Forecast to 2030

Image
Phosphodiesterase (PDE) inhibitors are a class of drugs that act on the phosphodiesterase enzymes , specifically the cyclic nucleotide phosphodiesterases. These enzymes are responsible for the degradation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important intracellular signaling molecules involved in various physiological processes. By inhibiting the activity of PDE enzymes, PDE inhibitors increase the levels of cAMP and cGMP in cells, leading to a variety of pharmacological effects. PDE inhibitors are used to treat a range of conditions, including erectile dysfunction, pulmonary arterial hypertension, and chronic obstructive pulmonary disease. They are available in different formulations, including oral tablets, sublingual tablets, and inhalers. There are several types of PDE enzymes, and PDE inhibitors are classified based on their selectivity for specific PDE enzyme subtypes. The major PDE inhibitors used in clinical practice ...
Read more

Enteral Nutrition Market will generate new growth opportunities 2023-2030

Image
Enteral nutrition is a method of providing nutrition directly into the gastrointestinal tract. It involves the delivery of a liquid formula containing nutrients through a tube, which can be inserted through the nose (nasogastric or nasoenteric tube) or directly into the stomach or small intestine (gastrostomy or jejunostomy tube). Enteral nutrition is typically used when a person is unable to consume an adequate amount of food orally or has a dysfunctional or non-functioning gastrointestinal tract. It may be used in various medical conditions such as: Inability to swallow: Patients who have difficulty swallowing due to conditions like stroke, neurological disorders, or head and neck cancers may require enteral nutrition to ensure adequate nutrition. Gastrointestinal disorders: Individuals with conditions such as Crohn's disease, short bowel syndrome, or malabsorption disorders may have difficulty absorbing nutrients from food, and enteral nutri...
Read more